BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15020279)

  • 1. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.
    Cairoli R; Grillo G; Tedeschi A; D'Avanzo G; Marenco P; Morra E
    Haematologica; 2004 Mar; 89(3):361-3. PubMed ID: 15020279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous stem cell transplantation in lymphoma.
    Schmitz N; Buske C; Gisselbrecht C
    Semin Hematol; 2007 Oct; 44(4):234-45. PubMed ID: 17961722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
    Pettengell R
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S1-4. PubMed ID: 11840153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.
    Kang TY; Rybicki LA; Bolwell BJ; Thakkar SG; Brown S; Dean R; Sekeres MA; Advani A; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
    Bone Marrow Transplant; 2007 Nov; 40(10):973-8. PubMed ID: 17873917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.
    Gianni AM; Cortelazzo S; Magni M; Martelli M;
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S10-3. PubMed ID: 11840155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.
    Thieblemont C; Antal D; Lacotte-Thierry L; Delwail V; Espinouse D; Michallet AS; Traulle C; Bouafia-Sauvy F; Giraud C; Salles G; Guilhot F; Coiffier B
    Cancer; 2005 Oct; 104(7):1434-41. PubMed ID: 16104036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
    J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
    Berinstein NL; Buckstein R; Imrie K; Spaner D; Mangel J; Tompkins K; Pennell N; Reis M; Pavlin P; Lima A; Couvadia A; Robinson J; Richardson P
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S14-7. PubMed ID: 11840156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hematopoietic stem cell transplantation for malignant lymphoma].
    Asaoku H
    Nihon Rinsho; 2000 Mar; 58(3):704-8. PubMed ID: 10741150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
    Miyazaki K; Masuya M; Yamaguchi M; Isaka S; Nakase K; Kobayashi T; Nakamura S; Shiku H
    Rinsho Ketsueki; 2005 Sep; 46(9):1065-70. PubMed ID: 16440766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.
    Bauwens D; Maerevoet M; Michaux L; Théate I; Hagemeijer A; Stul M; Danse E; Costantini S; Vannuffel P; Straetmans N; Vekemans MC; Deneys V; Ferrant A; Van Den Neste E
    Br J Haematol; 2005 Nov; 131(3):338-40. PubMed ID: 16225653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma.
    Kato H; Taji H; Ogura M; Kagami Y; Oki Y; Tsujimura A; Fuwa N; Kodaira T; Seto M; Yamamoto K; Morishima Y
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):443-8. PubMed ID: 19951884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
    Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG
    Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
    Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
    Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma.
    Imamura T; Yoshihara T; Morimoto A; Ishida H; Sugimoto T; Imashuku S
    Pediatr Hematol Oncol; 2006; 23(1):19-24. PubMed ID: 16326408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
    Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
    Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.
    de Guibert S; Jaccard A; Bernard M; Turlure P; Bordessoule D; Lamy T
    Haematologica; 2006 Mar; 91(3):425-6. PubMed ID: 16531272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.